hUC-MSC-Exo Therapy for Autoimmune Encephalitis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2027

Conditions
Autoimmune Encephalitis
Interventions
BIOLOGICAL

Human umbilical cord mesenchymal stem cell derived exosomes

Nasal spray of hUC-MSC-Exo (low dose: 2.5×10\^10 particles, mid-dose: 5.0×10\^10 particles, high-dose: 1.0×10\^11 particles), once per day for 7 days, then once per week for 3 weeks

OTHER

Placebo Control

Nasal spray of placebo control, once per day for 7 days, then once per week for 3 weeks

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ECHO Biotech

UNKNOWN

lead

Xuanwu Hospital, Beijing

OTHER

NCT07131683 - hUC-MSC-Exo Therapy for Autoimmune Encephalitis | Biotech Hunter | Biotech Hunter